Skip to main content

Advertisement

Table 1 Baseline characteristics of the 251 patients with N0-category nasopharyngeal carcinoma (NPC) and enlarged neck lymph nodes (ENLNs)

From: Clinical treatment considerations in the intensity-modulated radiotherapy era for patients with N0-category nasopharyngeal carcinoma and enlarged neck lymph nodes

Characteristic Total (cases) Small ENLN group [cases (%)] Large ENLN group [cases (%)] P valuea
Gender     0.923
 Male 194 66 (77.6) 128 (77.1)  
 Female 57 19 (22.4) 38 (22.9)  
Age (years)     0.661
 <50 167 55 (64.7) 112 (67.5)  
 ≥50 84 30 (35.3) 54 (32.5)  
Smoking     0.935
 Yes 73 25 (29.4) 48 (28.9)  
 No 178 60 (70.6) 118 (71.1)  
Drinking     0.836
 Yes 25 8 (9.4) 17 (10.2)  
 No 226 77 (90.6) 149 (89.8)  
LDH (U/L)     0.973
 <245 242 82 (96.5) 160 (96.4)  
 ≥245 9 3 (3.5) 6 (3.6)  
Family history of cancer     0.332
 Yes 87 26 (30.6) 61 (36.7)  
 No 164 59 (69.4) 105 (63.2)  
BED (Gy)     0.821
 <72 91 30 (35.3) 61 (36.7)  
 ≥72 160 55 (64.7) 105 (63.3)  
Chemotherapy     0.222
 Yes 152 47 (55.3) 105 (63.3)  
 No 99 38 (44.7) 61 (36.7)  
T categoryb     0.270
 T1 80 27 (31.8) 53 (31.9)  
 T2 54 24 (28.2) 30 (18.1)  
 T3 87 25 (29.4) 62 (37.3)  
 T4 30 9 (10.6) 21 (12.7)  
  1. The patients were divided into small and large ENLN groups using the cut-off value (5.5 mm) of the short diameter of the largest ENLN for the prediction of DFS
  2. LDH lactate dehydrogenase, BED biological equivalent dose
  3. a P values were calculated using the Chi square test or Fisher’s exact test if indicated
  4. bAccording to the 7th edition of the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) staging system